Are Broad-Spectrum Fluoroquinolones More Likely To Cause Clostridium difficile -Associated Disease?
- 1 September 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (9) , 3216-3219
- https://doi.org/10.1128/aac.00592-06
Abstract
Limited evidence suggests that broad-spectrum fluoroquinolones such as gatifloxacin and moxifloxacin are more likely to cause Clostridium difficile -associated disease than levofloxacin. In a population-based case-control study of outpatients prescribed fluoroquinolones, we found no increased risk of C. difficile -associated disease requiring hospitalization among patients prescribed gatifloxacin or moxifloxacin compared to levofloxacin.Keywords
This publication has 31 references indexed in Scilit:
- Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile-Associated Diarrhea: A Cohort Study during an Epidemic in QuebecClinical Infectious Diseases, 2005
- Blue Ribbon Abstract Award: Moxifloxacin use as a risk factor in an outbreak of Clostridium difficile–associated diseaseAmerican Journal of Infection Control, 2005
- A Large Outbreak ofClostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone UseInfection Control & Hospital Epidemiology, 2005
- A Hospital Outbreak of Clostridium difficile Disease Associated with Isolates Carrying Binary Toxin GenesClinical Infectious Diseases, 2005
- Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severityCMAJ : Canadian Medical Association Journal, 2004
- Clostridium difficile-associated diarrhea in adultsCMAJ : Canadian Medical Association Journal, 2004
- Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent AdultsClinical Infectious Diseases, 2003
- Bactericidal Activities of Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Aerobic and Anaerobic Respiratory Pathogens in SerumAntimicrobial Agents and Chemotherapy, 2003
- A Critical Review of the FluoroquinolonesDrugs, 2002
- Antibiotics andClostridium difficileNew England Journal of Medicine, 1999